The alpha 9-nicotinic acetylcholine receptor serves as a molecular target for breast cancer therapy

Journal of Experimental and Clinical Medicine

Volumn 3, Issue 6, 2011, Pages 246-251

  Ho, Yuan Soon ^a   Lee, Chia Hwa ^a   Wu, Chih Hsiung ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Breast cancer; Cigarette smoke; Nicotinic acetylcholine receptor

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ALPHA CONOTOXIN; ALPHA NEUROTOXIN; AZD 0328; BUNGAROTOXIN RECEPTOR; BUNGAROTOXIN RECEPTOR AGONIST; EPIGALLOCATECHIN GALLATE; ERYSODINE; ESTROGEN; EVP 6124; GARCINOL; ISPRONICLINE; LUTEOLIN; MEM 3454; MEM 63908; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR ALPHA9; NICOTINIC RECEPTOR BLOCKING AGENT; POLYPHENOL; QUERCETIN; R 3487; R 4996; S 24795; S 38232; SR 180711; TC 5619; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CARCINOGENESIS; DISEASE FREE SURVIVAL; DRUG TARGETING; HUMAN; LUNG CANCER; MALIGNANT TRANSFORMATION; NEUROPATHIC PAIN; NONHUMAN; PASSIVE SMOKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; SMOKING; UNSPECIFIED SIDE EFFECT;

EID: 83555179084     PISSN: 18783317     EISSN: 18783325     Source Type: Journal    
DOI: 10.1016/j.jecm.2011.10.007     Document Type: Review

References (94)

1. Changeux J.P., Kasai M., Lee C.Y. Use of a snake venom toxin to characterize the cholinergic receptor protein. Proc Natl Acad Sci U S A 1970, 67(3):1241-1247.
2. Clarke P.B., Schwartz R.D., Paul S.M., Pert C.B., Pert A. Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin. J Neurosci 1985, 5(5):1307-1315.
3. Lloyd G.K., Williams M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther 2000, 292(2):461-467.
4. Arneric S.P., Holladay M., Williams M. Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. Biochem Pharmacol 2007, 74:1092-1101.
5. Romanelli M.N., Gratteri P., Guandalini L., Martini E., Bonaccini C., Gualtieri F. Central nicotinic receptors: structure, function, ligands, and therapeutic potential. ChemMedChem 2007, 2:746-767.
6. Fayuk D., Yakel J.L. Dendritic Ca2+ signalling due to activation of alpha 7-containing nicotinic acetylcholine receptors in rat hippocampal neurons. J Physiol 2007, 582:597-611.
7. Lindstrom J.M. Nicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles, and vulnerability to pathology. Ann N Y Acad Sci 2003, 998:41-52.
8. Szabo S.I., Zelles T., Lendvai B. Intracellular Ca2+ dynamics of hippocampal interneurons following nicotinic acetylcholine receptor activation. Neurochem Int 2008, 52:135-141.
9. Flores C.M., DeCamp R.M., Kilo S., Rogers S.W., Hargreaves K.M. Neuronal nicotinic receptor expression in sensory neurons of the rat trigeminal ganglion: demonstration of alpha3beta4, a novel subtype in the mammalian nervous system. J Neurosci 1996, 16:7892-7901.
10. McCallum S.E., Collins A.C., Paylor R., Marks M.J. Deletion of the beta 2 nicotinic acetylcholine receptor subunit alters development of tolerance to nicotine and eliminates receptor upregulation. Psychopharmacology (Berl) 2006, 184:314-327.
11. Nelson M.E., Kuryatov A., Choi C.H., Zhou Y., Lindstrom J. Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors. Mol Pharmacol 2003, 63:332-341.
12. Zhou Y., Nelson M.E., Kuryatov A., Choi C., Cooper J., Lindstrom J. Human alpha4beta2 acetylcholine receptors formed from linked subunits. J Neurosci 2003, 23:9004-9015.
13. West K.A., Brognard J., Clark A.S., Linnoila I.R., Yang X., Swain S.M., Harris C., et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003, 111:81-90.
14. Albuquerque E.X., Pereira E.F., Castro N.G., Alkondon M., Reinhardt S., Schröder H., Maelicke A. Nicotinic receptor function in the mammalian central nervous system. Ann N Y Acad Sci 1995, 757:48-72.
15. Broide R.S., Leslie F.M. The alpha7 nicotinic acetylcholine receptor in neuronal plasticity. Mol Neurobiol 1999, 20:1-16.
16. Quik M., Philie J., Choremis J. Modulation of alpha7 nicotinic receptor-mediated calcium influx by nicotinic agonists. Mol Pharmacol 1997, 51:499-506.
17. Suzuki T., Hide I., Matsubara A., Hama C., Harada K., Andrä M., Matsubayashi H., et al. Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. J Neurosci Res 2006, 83:1461-1470.
18. Ho Y.S., Chen C.H., Wang Y.J., Pestell R.G., Albanese C., Chen R.J., Chang M.C., et al. Tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces cell proliferation in normal human bronchial epithelial cells through NFkappaB activation and cyclin D1 up-regulation. Toxicol Appl Pharmacol 2005, 205:133-148.
19. Chen R.J., Ho Y.S., Guo H.R., Yang Y.J. Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol Sci 2008, 104:283-293.
20. Wei P.L., Chang Y.J., Ho Y.S., Lee C.H., Yang Y.Y., An J., Lin S.Y. Tobacco-specific carcinogen enhances colon cancer cell migration through alpha7-nicotinic acetylcholine receptor. Ann Surg 2009, 249:978-985.
21. Lee C.H., Huang C.S., Chen C.S., Tu S.H., Wang Y.J., Chang Y.J., Tam K.W., et al. Overexpression and activation of the {alpha}9-nicotinic receptor during tumorigenesis in human breast epithelial cells. J Natl Cancer Inst 2010, 102(17):1322-1335.
22. Chen C.S., Lee C.H., Hsieh C.D., Ho C.T., Pan M.H., Huang C.S., Tu S.H., et al. Nicotine-induced human breast cancer cell proliferation attenuated by garcinol through down-regulation of the nicotinic receptor and cyclin D3 proteins. Breast Cancer Res Treat 2011, 125(1):73-87.
23. Shih Y.L., Liu H.C., Chen C.S., Tu S.H., Wang Y.J., Chang Y.J., Tam K.W., et al. Combination treatment with luteolin and quercetin enhances antiproliferative effects in nicotine-treated MDA-MB-231 cells by down-regulating nicotinic acetylcholine receptors. J Agric Food Chem 2010, 58:235-241.
24. Schuller H.M. Cell type specific, receptor-mediated modulation of growth kinetics in human lung cancer cell lines by nicotine and tobacco-related nitrosamines. Biochem Pharmacol 1989, 38:3439-3442.
25. Saccone S.F., Hinrichs A.L., Saccone N.L., Chase G.A., Konvicka K., Madden P.A., Breslau N., et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 2007, 16:36-49.
26. Maneckjee R., Minna J.D. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci U S A 1990, 87:3294-3298.
27. Maneckjee R., Minna J.D. Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ 1994, 5:1033-1040.
28. Cattaneo M.G., Codignola A., Vicentini L.M., Clementi F., Sher E. Nicotine stimulates a serotonergic autocrine loop in human small-cell lung carcinoma. Cancer Res 1993, 53:5566-5568.
29. Amos C.I., Gorlov I.P., Dong Q., Wu X., Zhang H., Lu E.Y., Greisinger A.J., et al. Nicotinic acetylcholine receptor region on chromosome 15q25 and lung cancer risk among African Americans: a case-control study. J Natl Cancer Inst 2010, 102:1199-1205.
30. Schuller H.M. Neurotransmission and cancer: implications for prevention and therapy. Anticancer Drugs 2008, 19:655-671.
31. Paleari L., Catassi A., Ciarlo M., Cavalieri Z., Bruzzo C., Servent D., Cesario A., et al. Role of alpha7-nicotinic acetylcholine receptor in human non-small cell lung cancer proliferation. Cell Prolif 2008, 41:936-959.
32. Zheng Y., Ritzenthaler J.D., Roman J., Han S. Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression. Am J Respir Cell Mol Biol 2007, 37:681-690.
33. Dasgupta P., Rastogi S., Pillai S., Ordonez-Ercan D., Morris M., Haura E., Chellappan S. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 2006, 116:2208-2217.
34. Arredondo J., Chernyavsky A.I., Grando S.A. The nicotinic receptor antagonists abolish pathobiologic effects of tobacco-derived nitrosamines on BEP2D cells. J Cancer Res Clin Oncol 2006, 132:653-663.
35. Trombino S., Cesario A., Margaritora S., Granone P., Motta G., Falugi C., Russo P. Alpha7-nicotinic acetylcholine receptors affect growth regulation of human mesothelioma cells: role of mitogen-activated protein kinase pathway. Cancer Res 2004, 64:135-145.
36. Paleari L., Grozio A., Cesario A., Russo P. The cholinergic system and cancer. Semin Cancer Biol 2008, 18:211-217.
37. Lee C.H., Chang Y.C., Chen C.S., Tu S.H., Wang Y.J., Chen L.C., Chang Y.J., et al. Crosstalk between nicotine and estrogen-induced estrogen receptor activation induces alpha9-nicotinic acetylcholine receptor expression in human breast cancer cells. Breast Cancer Res Treat 2011, 129:331-345.
38. Maskarinec G., Zhang Y., Takata Y., Pagano I., Shumay D.M., Goodman M.T., Le Marchand L., et al. Trends of breast cancer incidence and risk factor prevalence over 25 years. Breast Cancer Res Treat 2006, 98:45-55.
39. Al-Delaimy W.K., Cho E., Chen W.Y., Colditz G., Willet W.C. A prospective study of smoking and risk of breast cancer in young adult women. Cancer Epidemiol Biomarkers Prev 2004, 13:398-404.
40. Daniell H.W. Estrogen receptors, breast cancer, and smoking. N Engl J Med 1980, 302:1478.
41. Slattery M.L., Curtin K., Giuliano A.R., Sweeney C., Baumgartner R., Edwards S., Wolff R.K., et al. Active and passive smoking, IL6, ESR1, and breast cancer risk. Breast Cancer Res Treat 2008, 109:101-111.
42. Jacobi J., Jang J.J., Sundram U., Dayoub H., Fajardo L.F., Cooke J.P. Nicotine accelerates angiogenesis and wound healing in genetically diabetic mice. Am J Pathol 2002, 161:97-104.
43. Cooke J.P., Bitterman H. Nicotine and angiogenesis: a new paradigm for tobacco-related diseases. Ann Med 2004, 36:33-40.
44. Cooke J.P. Angiogenesis and the role of the endothelial nicotinic acetylcholine receptor. Life Sci 2007, 80:2347-2351.
45. Morimoto N., Takemoto S., Kawazoe T., Suzuki S. Nicotine at a low concentration promotes wound healing. J Surg Res 2008, 145:199-204.
46. Hauser T.A., Kucinski A., Jordan K.G., Gatto G.J., Wersinger S.R., Hesse R.A., Stachowiak E.K., et al. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol 2009, 78:803-812.
47. Teaktong T., Graham A.J., Court J.A., Perry R.H., Jaros E., Johnson M., Hall R., et al. Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer's disease and dementia with Lewy bodies: differential neuronal and astroglial pathology. J Neurol Sci 2004, 225:39-49.
48. Yu W.F., Guan Z.Z., Bogdanovic N., Nordberg A. High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Exp Neurol 2005, 192:215-225.
49. Jain R.K., Finn A.V., Kolodgie F.D., Gold H.K., Virmani R. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nat Clin Pract Cardiovasc Med 2007, 4:491-502.
50. Wu C.H., Lee C.H., Ho Y.S. Nicotinic acetylcholine receptor-based blockade: applications of molecular targets for cancer therapy. Clin Cancer Res 2011, 17:3533-3541.
51. Kitagawa H., Takenouchi T., Azuma R., Wesnes K.A., Kramer W.G., Clody D.E., Burnett A.L. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 2003, 28:542-551.
52. Levin E.D., Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 1998, 138:217-230.
53. Kellar K.J., Whitehouse P.J., Martino-Barrows A.M., Markus K., Price D.L. Muscarinic and nicotinic cholinergic binding sites in Alzheimer's disease cerebral cortex. Brain Res 1987, 436:62-68.
54. Marutle A., Warpman U., Bogdanovic N., Nordberg A. Regional distribution of subtypes of nicotinic receptors in human brain and effect of aging studied by (+/-)-[3H]epibatidine. Brain Res 1998, 801:143-149.
55. Perry D.C., Davila-Garcia M.I., Stockmeier C.A., Kellar K.J. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther 1999, 289:1545-1552.
56. Perry E., Martin-Ruiz C., Lee M., Griffiths M., Johnson M., Piggott M., Haroutunian V., et al. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 2000, 393:215-222.
57. Zanardi A., Leo G., Biagini G., Zoli M. Nicotine and neurodegeneration in ageing. Toxicol Lett 2002, 127:207-215.
58. Martin-Ruiz C.M., Court J.A., Molnar E., Lee M., Gotti C., Mamalaki A., Tsouloufis T., et al. Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem 1999, 73:1635-1640.
59. Lee P.N. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 1994, 13:131-144.
60. Biton B., Bergis O.E., Galli F., Nedelec A., Lochead A.W., Jegham S., Godet D., et al. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology 2007, 32:1-16.
61. Rezvani A.H., Kholdebarin E., Brucato F.H., Callahan P.M., Lowe D.A., Levin E.D. Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:269-275.
62. Sydserff S., Sutton E.J., Song D., Quirk M.C., Maciag C., Li C., Jonak G., et al. Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem Pharmacol 2009, 78:880-888.
63. Lopez-Hernandez G., Placzek A.N., Thinschmidt J.S., Lestage P., Trocme-Thibierge C., Morain P., Papke R.L. Partial agonist and neuromodulatory activity of S 24795 for alpha7 nAChR responses of hippocampal interneurons. Neuropharmacology 2007, 53:134-144.
64. Dunbar G., Demazieres A., Monreal A., Cisterni C., Metzger D., Kuchibhatla R., Luthringer R. Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers. J Clin Pharmacol 2006, 46:715-726.
65. Howe W.M., Ji J., Parikh V., Mocaër E., Trocmé-Thibierge C., Sarter M. Enhancement of attentional performance by selective stimulation of alpha4beta2(*) nAChRs: underlying cholinergic mechanisms. Neuropsychopharmacology 2010, 35:1391-1401.
66. Lagostena L., Danober L., Challal S., Lestage P., Mocaër E., Trocmé-Thibierge C., Cherubini E. Modulatory effects of S 38232, a non alpha-7 containing nicotine acetylcholine receptor agonist on network activity in the mouse hippocampus. Neuropharmacology 2010, 58:806-815.
67. Rollema H., Coe J.W., Chambers L.K., Hurst R.S., Stahl S.M., Williams K.E. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci 2007, 28:316-325.
68. Cohen C., Bergis O.E., Galli F., Lochead A.W., Jegham S., Biton B., Leonardon J., et al. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 2003, 306:407-420.
69. Sullivan J.P., Donnelly-Roberts D., Briggs C.A., Anderson D.J., Gopalakrishnan M., Xue I.C., Piattoni-Kaplan M., et al. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther 1997, 283:235-246.
70. Pomerleau O.F., Downey K.K., Stelson F.W., Pomerleau C.S. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 1995, 7:373-378.
71. Wilens T.E., Verlinden M.H., Adler L.A., Wozniak P.J., West S.A. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry 2006, 59:1065-1070.
72. Lippiello P.M., Beaver J.S., Gatto G.J., James J.W., Jordan K.G., Traina V.M., Xie J., et al. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci Ther 2008, 14:266-277.
73. Luetje C.W., Wada K., Rogers S., Abramson S.N., Tsuji K., Heinemann S., Patrick J. Neurotoxins distinguish between different neuronal nicotinic acetylcholine receptor subunit combinations. J Neurochem 1990, 55:632-640.
74. Decker M.W., Anderson D.J., Brioni J.D., Donnelley-Roberts D.L., Kang C.H., O'Neill A.B., Piattoni-Kaplan M., et al. Erysodine, a competitive antagonist at neuronal nicotinic acetylcholine receptors. Eur J Pharmacol 1995, 280:79-89.
75. Holladay M.W., Dart M.J., Lynch J.K. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Chem 1997, 40:4169-4194.
76. Schuller H.M. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors?. Nat Rev Cancer 2009 Mar, 9(3):195-205. [Epub 2009 Feb 5].
77. Sciamanna M.A., Griesmann G.E., Williams C.L., Lennon V.A. Nicotinic acetylcholine receptors of muscle and neuronal (alpha7) types coexpressed in a small cell lung carcinoma. J Neurochem 1997, 69:2302-2311.
78. Sandall D.W., Satkunanathan N., Keays D.A., Polidano M.A., Liping X., Pham D., Down J.G., et al. A novel alpha-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo. Biochemistry 2003, 42:6904-6911.
79. Heeschen C., Jang J.J., Weis M., Pathak A., Kaji S., Hu R.S., Tsao P.S., et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001, 7:833-839.
80. Heeschen C., Weis M., Aicher A., Dimmeler S., Cooke J.P. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest 2002, 110:527-536.
81. Heeschen C., Weis M., Cooke J.P. Nicotine promotes arteriogenesis. J Am Coll Cardiol 2003, 41:489-496.
82. Dasgupta P., Kinkade R., Joshi B., Decook C., Haura E., Chellappan S. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A 2006, 103:6332-6337.
83. Damaj M.I., Glassco W., Aceto M.D., Martin B.R. Antinociceptive and pharmacological effects of metanicotine, a selective nicotinic agonist. J Pharmacol Exp Ther 1999, 291:390-398.
84. Gilbert S.D., Clark T.M., Flores C.M. Antihyperalgesic activity of epibatidine in the formalin model of facial pain. Pain 2001, 89:159-165.
85. Wang Y., Su D.M., Wang R.H., Liu Y., Wang H. Antinociceptive effects of choline against acute and inflammatory pain. Neuroscience 2005, 132:49-56.
86. Peng C., Tang S., Pi C., Wang F., Wang L., Zhou W., Xu A. Discovery of a novel class of conotoxin from Conus litteratus, lt14a, with a unique cysteine pattern. Peptides 2006, 27:2174-2181.
87. Satkunanathan N., Livett B., Gayler K., Sandall D., Down J., Khalil Z. Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones. Brain Res 2005, 1059:149-158.
88. Vincler M., Wittenauer S., Parker R., Ellison M., Olivera B.M., McIntosh J.M. Molecular mechanism for analgesia involving specific antagonism of alpha9alpha10 nicotinic acetylcholine receptors. Proc Natl Acad Sci U S A 2006, 103:17880-17884.
89. Livett B.G., Sandall D.W., Keays D., Down J., Gayler K.R., Satkunanathan N., Khalil Z. Therapeutic applications of conotoxins that target the neuronal nicotinic acetylcholine receptor. Toxicon 2006, 48:810-829.
90. Wang Y., Wang Z., Wang L., Zhou Y., Zhao Y., Liu L., Yao C., et al. Estrogen down-regulates nicotine-induced adhesion molecule expression via nongenomic signal pathway in endothelial cells. Int Immunopharmacol 2006, 6:892-902.
91. Lin Y.S., Tsai Y.J., Tsay J.S., Lin J.K. Factors affecting the levels of tea polyphenols and caffeine in tea leaves. J Agric Food Chem 2003, 51:1864-1873.
92. Lin J.K., Chen P.C., Ho C.T., Lin-Shiau S.Y. Inhibition of xanthine oxidase and suppression of intracellular reactive oxygen species in HL-60 cells by theaflavin-3,3'-digallate, (-)-epigallocatechin-3-gallate, and propyl gallate. J Agric Food Chem 2000, 48:2736-2743.
93. Suzuki Y., Tsubono Y., Nakaya N., Suzuki Y., Koizumi Y., Tsuji I. Green tea and the risk of breast cancer: pooled analysis of two prospective studies in Japan. Br J Cancer 2004, 90:1361-1363.
94. Tu S.H., Ku C.Y., Ho C.T., Chen C.S., Huang C.S., Chen L.C., Pan M.H., et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits nicotine- and estrogen-induced alpha9-nicotinic acetylcholine receptor upregulation in human breast cancer cells. Mol Nutr Food Res 2011, 55:455-466.